Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERSE-LC: Baricitinib for Long COVID
NCT06631287Phase 3Recruiting
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-COVID-19 condition (PCC) comparing Baricitinib with Placebo (2 arms). Primary endpoint: CNS-Vital Signs Global Cognitive Index at 6 months. Started Oct 2024; status: recruiting.
02
Drugs
baricitinib
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06631287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631287.